Patents Assigned to Ribozyme Pharmaceuticals, Inc.
  • Synthesis, deprotection, analysis and purification of RNA and ribozymes
    Patent number: 5977343
    Abstract: Method for purification and synthesis of RNA molecules and enzymatic RNA molecules in enzymatically active form.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: November 2, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Danuta Tracz
  • HIV nef targeted ribozymes
    Patent number: 5972704
    Abstract: An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: October 26, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Kenneth G. Draper, Bharat Chowrira, James McSwiggen, Dan T. Stinchcomb, James D. Thompson
  • Method and reagent for inhibiting herpes simplex virus replication
    Patent number: 5972699
    Abstract: An enzymatic RNA molecule which specifically cleaves a herpes simplex virus mRNA molecule.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: October 26, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • Chemical syntheses of 2'-O-methoxy purine nucleosides
    Patent number: 5962675
    Abstract: Several processes for the chemical synthesis of 2'-O-methoxy purine nucleosides are herein disclosed.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: October 5, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Leonid Beigelman, David Sweedler, Peter Haeberli, Alexander Karpeisky
  • RNA polymerase III-based expression of therapeutic RNAs
    Patent number: 5902880
    Abstract: A transcribed non-naturally occuring RNA molecule comprising a desired RNA molecule, wherein the 3' region of the RNA is able to base-pair with at least 8 bases at the 5' terminus of the same RNA molecule.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: May 11, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: James Thompson
  • Base-modified enzymatic nucleic acid
    Patent number: 5891684
    Abstract: Method to produce a more active ribozyme by introducing a modified base into a substrate binding arm of the ribozyme or its catalytic core.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: April 6, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Nassim Usman, Leonid Beigelman, James McSwiggen, Alex Karpeisky
  • Non-nucleotide containing enzymatic nucleic acid
    Patent number: 5891683
    Abstract: Enzymatic nucleic acid molecule containing one or more non-nucleotide mimetics, and having activity to cleave an RNA or DNA molecule.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: April 6, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Nassim Usman, Francine Wincott, Jasenka Matulic-Adamic, Leonid Beigelman, Alex Karpeisky
  • Base-modified enzymatic nucleic acid
    Patent number: 5879938
    Abstract: Method to produce a more active ribozyme by introducing a modified base into a substrate binding arm of the ribozyme or its catalytic core.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: March 9, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Nassim Usman, Leonid Beigelman, James McSwiggen, Alex Karpeisky
  • B7-1 targeted ribozymes
    Patent number: 5877021
    Abstract: Nucleic acid molecule which blocks synthesis and/or expression of an mRNA encoding B7-1.
    Type: Grant
    Filed: January 12, 1996
    Date of Patent: March 2, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Thale Jarvis, James McSwiggen
  • Ribozymes targeted to APO(a) RNA
    Patent number: 5877022
    Abstract: Enzymatic RNA molecules which cleave apo(a) mRNA.
    Type: Grant
    Filed: December 26, 1996
    Date of Patent: March 2, 1999
    Assignees: Ribozyme Pharmaceuticals, Inc, Warner Lambert
    Inventors: Dan T. Stinchcomb, James McSwiggen, Roger S. Newton, Randy Ramharack
  • Method and reagent for inhibiting hepatitis C virus replication
    Patent number: 5869253
    Abstract: An enzymatic RNA molecule which specifically cleaves RNA of a hepatitis C virus.
    Type: Grant
    Filed: December 26, 1996
    Date of Patent: February 9, 1999
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventor: Kenneth G. Draper
  • Catalytic DNA
    Patent number: 5861288
    Abstract: Nucleic acid able to cause specific cleavage of a bond between two ribonucleotides in an RNA-containing molecule. The RNA-containing molecule has the structure:5'-XnUHZCUGANGAGYm-3'wherein each X and Y is independently any nucleotide base; n and m are independently between 5 and 40; H is U, A or C; Z is a hairpin loop, having between 6 and 60 bases, and each U, C, G and A is a uracil, cytosine, guanosine, or adenosine-containing ribonucleotide, respectively, and N is any ribonucleotide. The nucleic acid has the structure:3'-X'nM.sub.0 Y'm-5'wherein each X' and Y' are complementary nucleotide bases to each corresponding X and Y, and M.sub.0 is a series of nucleotide bases active to cause the cleavage, and wherein M.sub.0 contains no ribonucleotides.
    Type: Grant
    Filed: October 18, 1993
    Date of Patent: January 19, 1999
    Assignees: Ribozyme Pharmaceuticals, Inc., UAB Research Foundation, University of Montreal
    Inventors: Nassim Usman, Robert J. Cedergren, Pascal Chartrand, Stephen C. Harvey
  • 2'-O-alkylthioalkyl and 2'-C-alkylthioalkyl-containing nucleic acids
    Patent number: 5840876
    Abstract: A compound having the formula: ##STR1## wherein, R1 represents 2'-O-R.sub.3 -thio-R.sub.3 and/or 2'-C-R.sub.3 -thio-R.sub.3, wherein R.sub.3 is independently a compound selected from a group consisting of alkyl, alkenyl, alkynyl, aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester; X represents a base or H; Y represents a phosphorus-containing group; and R2 represents H, DMT or a phosphorus-containing group.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: November 24, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Leonid Beigelman, Alex Karpeisky
  • Hairpin ribozymes
    Patent number: 5837855
    Abstract: Hairpin ribozyme lacking a substrate moiety, comprising at least six bases in helix 2 and able to base-pair with a separate substrate RNA, wherein the said ribozyme comprises one or more bases 3' of helix 3 able to base-pair with the said substrate RNA to form a helix 5 and wherein the said ribozyme can cleave and/or ligate said separate RNA(s) in trans.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: November 17, 1998
    Assignee: Ribozyme Pharmaceutical, Inc.
    Inventors: Bharat Chowrira, James McSwiggen
  • Intercellular adhesion molecule-1 (ICAM-1) ribozymes
    Patent number: 5837542
    Abstract: Enzymatic RNA molecules which cleave ICAM-1 mRNA.
    Type: Grant
    Filed: August 17, 1994
    Date of Patent: November 17, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Susan Grimm, Dan T. Stinchcomb, James McSwiggen, Sean Sullivan, Kenneth G. Draper
  • Synthesis deprotection analysis and purification of RNA and ribozymes
    Patent number: 5831071
    Abstract: A process for deprotecting RNA 2'-O-alkylsilyl groups comprising, contacting the groups with a solution of anhydrous triethylamine-hydrogen fluoride (aHF-TEA) in triethylamine and N-methylpyrrolidine at between 60.degree. C.-70.degree. C. for 0.25-24 h.
    Type: Grant
    Filed: August 29, 1997
    Date of Patent: November 3, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Nassim Usman, Francine Wincott
  • TNF-.alpha. ribozymes
    Patent number: 5811300
    Abstract: Enzymatic RNA molecules which cleave TNF-.alpha. mRNA.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: September 22, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Sean Sullivan, Kenneth Draper, Kevin Kisich, Dan T. Stinchcomb, James McSwiggen
  • Interleukin-2 receptor gamma-chain ribozymes
    Patent number: 5807743
    Abstract: A nucleic acid molecule which blocks synthesis and/or expression of an IL-2R encoded RNA, wherein said nucleic acid molecule is used to treat graft rejection, an autoimmune disease, cancer, psoriasis, an allergy or other inflammatory disease.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: September 15, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, James A. McSwiggen
  • Deprotection of RNA with alkylamine
    Patent number: 5804683
    Abstract: A method for the deprotection of RNA comprising reacting an alkylamine or ammonium hydroxide/alkylamine mixture with the RNA at 60-70 degrees Centigrade for 5 to 15 minutes in order to remove any exocyclic protecting groups, wherein said alkylamine is selected from the group consisting of ethylamine, propylamine, and butylamine.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: September 8, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Nassim Usman, Francine E. Wincott, Danuta Tracz
  • Enzymatic RNA with activity to RAS
    Patent number: 5801158
    Abstract: An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of colon carcinoma.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: September 1, 1998
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: James D. Thompson, Kenneth G. Draper